The change of ocular biometry in ophthalmic patients who received anti-VEGF therapy

The change of ocular biometry in ophthalmic patients who received anti-VEGF therapy - The change of ocular biometry in ophthalmic patients who received anti-VEGF therapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031895

Enrollment

100

Registered

2018-03-26

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with vitreoretinal diseases who need anti-VEGF therapy

Interventions

anterior segment biometry (CASIA, TMS-5), axial length, stereoscopic vision, metamorphopsia, contrast sensitivity, visual acuity, intraocular pressure, frequency and degree of complex, degree of cryst

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with retinal diseases who need anti-VEGF therapy

Exclusion criteria

Exclusion criteria: Patients ruled unfit to the study by investigator

Design outcomes

Primary

Measure	Time frame
axial length, degree of crystalline lens opacity, functional visual acuity, contrast sensitivity, stereoscopic vision, metamorphopsia, color vision, microperimetry, retinal form, corneal biometry, VFQ-25	—

Secondary

Measure	Time frame
visual acuity, intraocular pressure, frequency and degree of anti-VEGF injection complex	—

Countries

Japan

Contacts

Public ContactYoshifumi Okamoto

University of Tsukuba Department of Ophthalmology, Faculty of Medicine

y-okamoto@md.tsukuba.ac.jp0298533148

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026